Atlas Trials

Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy

Clinical trial NCT06691594 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06691594
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer Invasive
Start date
2025-02-01
Primary completion
2028-11-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.